Inhibition of HIV-1 replication by an antiviral xanthate compound in vitro.
The antiviral xanthate compound tricyclodecan-9-yl-xanthogenate (code name D609) is capable of inhibiting DNA and RNA viruses in vitro. It can also inhibit the shedding of infectious HIV into the tissue culture medium from chronically infected lymphoma cells (KE37-III) as shown by infectivity assays and Western blots of the supernatant. HIV-specific proteins, however, were accumulated intracellularly. The initiation of a de novo HIV replication after infection of permissive KE37-1 cells was completely inhibited at concentrations of D609 which still permitted mitotic divisions of the cells. Furthermore, the selective antiviral activity of the xanthate compound was evidenced by the absence of HIV replicative intermediate DNA. The expression of cellular genes, such as c-myc, remained unimpaired within these cells.
Mellert
W
W
Abt. für Molekulare Zellpathologie, Gesellschaft für Strahlen und Umweltforschung (GSF), Neuherberg/München, West Germany.
Amtmann
E
E
Erfle
V
V
Sauer
G
G
D000998:Antiviral Agents / Q000494:pharmacology; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009636:Norbornanes; D011519:Proto-Oncogenes / Q000187:drug effects; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D001952:Bridged-Ring Compounds; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; C046498:tricyclodecane-9-yl-xanthogenate